- Home
- FORR vs WHWK Comparison
FORR vs WHWK Comparison
Compare FORR & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORR | WHWK |
|---|---|---|
| Founded | 1983 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.6M | 95.2M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | FORR | WHWK |
|---|---|---|
| Price | $6.32 | $3.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 193.4K | 147.8K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.91 | $1.39 |
| 52 Week High | $11.57 | $4.40 |
Technical Indicators
Market Signals| Indicator | FORR | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 70.48 |
| Support Level | $5.02 | $1.84 |
| Resistance Level | $6.71 | N/A |
| Average True Range (ATR) | 0.40 | 0.28 |
| MACD | 0.11 | 0.07 |
| Stochastic Oscillator | 76.83 | 71.03 |
Price Performance
Historical ComparisonAbout FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.